Richard Kocharian

Richard Kocharian

Auto-generated profile, based on publicly available information

Richard Kocharian

Ethicon, Inc., Raritan, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Medical Devices: Evidence and Research
Verified
Journal Article
Open access
PDF file
MMMelinda H MacDonald
Melinda H MacDonald
AWAllen Y Wang
Allen Y Wang
JCJeffrey Clymer
Jeffrey Clymer
RHRichard W Hutchinson
Richard W Hutchinson
RKRichard Kocharian
Richard Kocharian
Background: Usage of topical hemostatic agents in surgery is increasing, including use during minimally invasive procedures, and even for surgeries that have a low risk of bleeding complications. A novel product, Surgicel® Powder – Absorbable Hemostatic Powder (SP), made from oxidized regenerated cellulose (ORC) fabric, has been developed for adjunctive use in surgical procedures to assist in control of oozing bleeding over broad areas and where access could be difficult with a fabric ORC product. This study compares the new SP to other commercially available hemostatic powder products in two in vivo models. Methods: Hemostatic efficacy of SP was compared to two polysaccharide-based hemostats in a porcine liver punch biopsy model and to three polysaccharide-based hemostats and one non-regenerated oxidized cellulose hemostat in a porcine liver abrasion model. Primary outcomes measured were hemostatic efficacy, defined as hemostasis within 10 minutes of application, and time-to-hemostasis (TTH). Results: In the punch biopsy model, SP displayed significantly higher effective hemostasis rates than one of the polysaccharide hemostats (p=0.047) and faster TTH than both (p<0.001). In the liver abrasion model, SP had significantly higher effective hemostasis rates (p≤0.002) and faster TTH (p<0.001) than the other four hemostatic agents. The amount of powder applied within the ranges used did not appear to affect hemostatic efficacy. Conclusion: In both the liver punch biopsy model of mild to moderate bleeding and the liver abrasion model of mild but diffuse oozing, SP provided more effective hemostasis and faster TTH than other marketed hemostatic powders. The results from this in vivo study suggest that Surgicel Powder may be useful in clinical applications where control of oozing capillary, mild venous, and small arterial hemorrhage is required including bleeding in difficult-to-access locations.

10 May 2024 in Child's Nervous System
Verified
Journal Article
Open access
PDF file
GSGnanamurthy Sivakumar
Gnanamurthy Sivakumar
SMShailendra Magdum
Shailendra Magdum
KAKristian Aquilina
Kristian Aquilina
JKJothy Kandasamy
Jothy Kandasamy
VJVivek Josan
Vivek Josan
BPBenedetta Pettorini
Benedetta Pettorini
Purpose: Cerebrospinal fluid (CSF) leakage is a challenging complication of intradural cranial surgery, and children are particularly at risk. The use of dural sealants confers protection in adults, but pediatric studies are scarce. We evaluated the safety and efficacy of Evicel® fibrin sealant as an adjunct to primary dural suturing in children undergoing cranial surgery. Methods: A multicenter trial prospectively enrolled pediatric subjects (< 18 years) undergoing cranial neurosurgery who, upon completion of primary sutured dural repair, experienced CSF leakage. As agreed by the EMA Evicel® Pediatric Investigation Plan, 40 subjects were intra-operatively randomized 2:1 to Evicel® or additional sutures (‘Sutures’). Data analysis was descriptive. The efficacy endpoint was treatment success rate, with success defined as intra-operative watertight closure after provocative Valsalva maneuver (primary endpoint). Safety endpoints were postoperative CSF leakage (incisional CSF leakage, pseudomeningocele or both) and surgical site complications (secondary endpoints). Results: Forty subjects (0.6–17 years) were randomized to Evicel® (N = 25) or Sutures (N = 15) (intention-to-treat). Intracranial tumor was the most common indication and procedures were mostly supratentorial craniotomies. Success rates were 92.0% for Evicel® and 33.3% for Sutures, with a 2.76 estimated ratio of success rates (Farrington-Manning 95% CI [1.53, 6.16]). Sensitivity analyses in per-protocol and safety sets showed similar results. Despite a higher rescue treatment rate, the frequencies of postoperative CSF leakage and wound complications were higher for Sutures than for Evicel®. Conclusion: This small-scale prospective study shows Evicel® treatment to be safe and effective as an adjunct to primary sutured dura mater closure in a pediatric population. Compared to additional sutures, Evicel® was associated with reduced postoperative CSF leakage and surgical site complications. (Trial registration: The trial was registered as NCT02309645 and EudraCT 2013-003558-26).

1 May 2015 in Value in Health
Verified
Journal Article
Closed access
PDF file
CGC. Gunnarsson
C. Gunnarsson
SLS. Lim
S. Lim
GDG. David
G. David
JRJ.B. Riebman
J.B. Riebman
LML. Martin
L. Martin
RKR. Kocharian
R. Kocharian

12 July 2024 in Child's Nervous System
Verified
Journal Article
Open access
PDF file
GSGnanamurthy Sivakumar
Gnanamurthy Sivakumar
SMShailendra Magdum
Shailendra Magdum
KAKristian Aquilina
Kristian Aquilina
JKJothy Kandasamy
Jothy Kandasamy
VJVivek Josan
Vivek Josan
BPBenedetta Pettorini
Benedetta Pettorini